MML Investors Services
AXSM icon

MML Investors Services’s Axsome Therapeutics AXSM Stock Holding History

MML Investors Services’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$357K Sell
2,113
-275
-12% -$47.5K ﹤0.01% 2454
2025
Q4 		$436K Buy
+2,388
New +$333K ﹤0.01% 2356

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MML Investors Services's AXSM Position: Q1 2026 in Review

MML Investors Services reduced its Axsome Therapeutics (AXSM) stake by 12% in Q1 2026, selling an estimated $47.5K and leaving 2,113 shares worth $357K. The position accounts for ﹤0.01% of the portfolio, ranked #2454.

MML Investors Services first reported a position in AXSM in Q4 2025 and has held it in 2 quarters since. The position peaked at $436K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • MML Investors Services held 2,113 shares of Axsome Therapeutics worth $357K as of Q1 2026.
  • MML Investors Services sold 275 Axsome Therapeutics shares in Q1 2026, an estimated $47.5K.
  • Axsome Therapeutics made up ﹤0.01% of MML Investors Services's portfolio in Q1 2026, its #2454 holding.
  • MML Investors Services first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • MML Investors Services's Axsome Therapeutics position peaked at $436K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on MML Investors Services's 13F filing for Q1 2026, filed 4 May 2026.